You are here

  • Home
  • Archive
  • Volume 66, Issue 3
  • Analysis of response to infliximab in ankylosing spondylitis according to the axial and/or peripheral involvement: autoantibodies and drop outs are more frequent in the peripheral subset

Article Text

Article menu
Download PDFPDF
Letter
Analysis of response to infliximab in ankylosing spondylitis according to the axial and/or peripheral involvement: autoantibodies and drop outs are more frequent in the peripheral subset
  1. Marco Maria Lizzio,
  2. Giusy Peluso,
  3. Angelo Zoli,
  4. Elisa Gremese,
  5. Barbara Tolusso,
  6. GianFranco Ferraccioli
  1. Division of Rheumatology, Catholic University, Rome, Italy
  1. Correspondence to:
    Dr G F Ferraccioli
    Department of Rheumatology, UCSC School of Medicine, Catholic University of Rome, via Moscati 31, 00168 Rome, Italy; gf.ferraccioli{at}rm.unicatt.it

http://dx.doi.org/10.1136/ard.2006.065052

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Infliximab, a monoclonal antibody that targets membrane and soluble tumour necrosis factor (TNF)α, has recently been successfully used to treat patients with active ankylosing spondylitis.1,2 No distinction in terms of axial or peripheral involvement has ever been considered in evaluating the clinical response and autoantibody induction secondary to the infliximab regimen in patients with ankylosing spondylitis.

    In this study, we evaluated the effectiveness and tolerability of infliximab in 23 patients with ankylosing spondylitis with only axial involvement (ASaxial) and in 24 patients with ankylosing spondylitis with axial and peripheral arthritis (ASperipheral) (Bath Ankylosis Spondylitis Disease Activity Index (BASDAI) ⩾4),3 and the occurrence of autoantibody induction4–7 in the two different subsets and their clinical relevance in terms of outcome. All patients received infliximab (5 mg/kg) according to …

    View Full Text

    Footnotes

    • Competing interests: None declared.